Coronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.
Margaret E. Gatti-Mays, MD, MPH, FACP, evaluates the evolution of immunotherapy in cases of breast cancer for Breast Cancer Awareness Month.
Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.
The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.
Theodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.
Murugesan Manoharan, MD, FRACS, offers observations about prostate cancer care at Miami Cancer Institute.
Christopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Ruta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
A number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.
Wojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.
Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.
Thomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Pashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.
Fadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.
Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Andrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.
In an interview with Targeted Oncology™, Rohan Garje, MD, discussed available therapies, how to assess risks, and manage toxicities for patients with renal cell carcinoma.
Hearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.
Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.
Next generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.
Adam Weiner, MD, discusses the results of his research on molecular subtyping in prostate cancer.
The phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.
David W. Dougherty, MD, MBA, discusses telemedicine in oncology after emergence of COVID-19.
Gary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.